Please login to the form below

Not currently logged in
Email:
Password:

Professor Carole Longson moves from NICE to the ABPI

She joins the UK pharma body as its chief scientific officer

The Association of the British Pharmaceutical Industry (ABPI) has attracted Professor Carole Longson away from the National Institute for Health and Care Excellence (NICE) to be its new chief scientific officer, handing her responsibility for leading the UK trade body's research, medical and innovation functions.

She will also shape and develop UK pharmaceutical science policy and will ensure that the UK “remains at the forefront of innovation in medicines research, development and manufacturing”.

Mike Thompson, chief executive of the ABPI, said: “The appointment of Carole to this new post signals our commitment to strengthening our focus on science, research and discovery in the UK and the role our members play in developing new innovative medicines and vaccines.

“Her scientific research and academic experience, along with her integrity, perspective and vision can really help us continue to transform the pharmaceutical industry in the UK.”

Longson brings research, academic and pharmaceutical industry experience to the ABPI, including seven years as a research lead at GlaxoSmithKline.

She most recently spent the 18 years at the National Institute for Health and Care Excellence (NICE), where she has led the HTA organisation’s technology appraisal programme.

Neil Weir, chair of the ABPI innovation board, said: “I am delighted by the appointment of Carole to the role of chief scientific officer at the ABPI and her significant scientific experience, expertise and network in both industry and academia will enable the ABPI to work with our partners to further these objectives.”

30th January 2018

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics